Michael Abramo's Contact Details

Michael Abramo's Company Details

Imaging Endpoints

Scottsdale, Arizona, US • 219 Employees
Major Drugs

Imaging Endpoints (IE) is passionately focused on our vision to Connect Imaging to the Cure. We have supported the most impactful new drug approvals in oncology, have achieved a perfect inspection record and a remarkable 95% regulatory approval success rate in over 150 successful marketing authorizations. • LOCATIONS: Imaging Endpoints is based in Scottsdale, AZ, with offices in Cambridge, Massachusetts, USA; London, United Kingdom; Leiden, Netherlands; Basel, Switzerland; Hyderabad, India; and Shanghai, China. • AFFILIATES: We are an affiliate of HonorHealth, one of the largest healthcare systems nationally. We are also an affiliate of Scottsdale Medical Imaging, Ltd., part of the largest private radiology group in the US. • DEEP SCIENCE: Our Medical and Scientific Affairs Team includes world-class leaders in imaging science. Over 50 publications in leading journals have established us as a technology leader. IE’s experience spans hundreds of successful studies across all phases of development, including the most complex and high-profile Phase 3 trials in the industry. • EXPERT READERS: Our team includes over 200 physician readers comprised of > 50 in-house radiologists and academically based expert radiologists, oncologists, surgeons and other physicians. • GLOBAL SERVICES: We are the largest global imaging CRO in oncology. We receive/read scans in real-time from thousands of imaging sites across the globe. • SETTING NEW QUALITY STANDARDS: Our imaging Quality Management System (iQMS) is designed to exceed industry standards. All inspections by FDA, EMEA, and a dozen of the top regulatory agencies globally have resulted in zero observations, clearly demonstrating our leadership in quality. • EXCEPTIONAL STABILITY: IE has experienced 15 years of high growth with no ownership change or executive leadership change in a decade - and turnover of staff and physician readers is exceptionally low.